Monographie - Ceftazidime Avibactam - Stabilis 4.0

zadnja posodobitev :
19/11/2024

Antibiotik

Ceftazidime Avibactam

Brizgalka

Stabilnost raztopine

Stabilnost mešanice

Faktorji, ki vplivajo na stabilnost

Kompatibilnost

način aplikacije

Viri

pdf

Kemična formula

Lastniško ime

Lastniško ime

Sestava pomožnih snovi je med paralelami lahko različna

Avycaz	Združene države Amerike
Torgena	Brazilija
Zavicefta	Argentina, Avstralija, Belgija, Čile, Finska, Francija, Irska, Italija, Luksemburg, Madžarska, Mehika, Nemčija, Norveška, Peru, Romunija, Slovenija, Španija, Švedska, Švica, Tunizija, Velika Britanija, Združene države Amerike

Viri

Brizgalka

Viri : Ceftazidime Avibactam

	Tip	objava
2902	Traduction Laboratorij	Ceftazidime - avibactam (Avycaz®) - Summary of Product Characteristics Forrest Pharmaceuticals 2015
3520	Traduction Laboratorij	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Traduction Laboratorij	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Traduction Laboratorij	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Traduction Laboratorij	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3984	časopis	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
4055	časopis	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	časopis	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4434	časopis	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	časopis	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4548	časopis	O'Donnell J.N, Xu A, Lodise T.P. Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration. Clin Ther 2020 ; 42, 8: 1580-1586.
4634	časopis	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4801	časopis	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4822	časopis	Naicker S, Roberts J.A, Won H, Wallis S.C, Unwin S, Jamieson C, Hills T, Gilchrist M, Santillo M, Seaton R.A, Drummond F, Sime Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. JAC Antimicrob Resist 2024

Mentions Légales